Cannabis use and psychosis: a review of reviews
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
We conducted a systematic review of meta-analyses and systematic reviews to evaluate the impact of cannabis use on the onset and course of psychoses. Following a systematic literature search of five data bases (2005-2016) and consecutive structured evaluation, we were able to include 26 systematic reviews and meta-analyses. The methodological quality of the included publications were in the range of high and poor. The scientific literature indicates that psychotic illness arises more frequently in cannabis users compared to non-users, cannabis use is associated with a dose-dependent risk of developing psychotic illness, and cannabis users have an earlier onset of psychotic illness compared to non-users. Cannabis use was also associated with increased relapse rates, more hospitalizations and pronounced positive symptoms in psychotic patients. We make recommendations about the type of research that is required to better characterize the relationship between cannabis use and the development and outcomes of psychosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analyses of case–control and cohort studies report a robust association between cannabis use and the risk of a psychotic disorder, and a dose–response relationship between this risk and the frequency of cannabis use [16].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [16]
In the citing paper
“Meta-analyses of case–control and cohort studies report a robust association between cannabis use and the risk of a psychotic disorder, and a dose–response relationship between this risk and the frequency of cannabis use [16].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [16]
In the citing paper
“guanfacine treatment may also be protective in the prodrome to mental illness in high risk adolescents who are cannabis users.”
From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Hasan et al., 2020
In the citing paper
“As cannabis use in adolescents is a risk factor for subsequent schizophrenia (Hasan et al., 2020)”
From Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species (2020) · cites this paper as Hasan et al., 2020
In the citing paper
“An umbrella review (2020) involving four meta-analyses found a dose–response relationship between cannabis use and the risk of psychosis (Hasan et al., 2020).”
From Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis (2023) · cites this paper as Hasan et al., 2020
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,171
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 2×
“To answer this first research question, we analyzed five meta-analyses [31, 33–35 Kraan et al. [31] (SIGN++, LoE1) included seven prospective longitudinal studies with a total of 1171 at-risk subjects.”
Methodology in conducting a systematic review of systematic reviews of healthcare interventions
Smith, V., Devane, D., Begley, C. M., & Clarke, M. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-15 · Cited by 1,227 · cited 1×
“More recently, calls have been made for ‘rapid reviews’ to provide decision-makers with the evidence they need in a shorter time frame [19].”
Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?
Bastian, H., Glasziou, P., & Chalmers, I. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000326 · Cited by 1,188 · cited 1×
“In recent years, however, decision makers who were once overwhelmed by the number of individual studies have become faced by a flood of reviews [18].”
Linscott, R. J., & van Os, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712001626 · Cited by 1,181 · cited 2×
“To answer this first research question, we analyzed five meta-analyses [31, 33–35 Kraan et al. [31] (SIGN++, LoE1) included seven prospective longitudinal studies with a total of 1171 at-risk subjects.”
InfluentialThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907 · cited 1×
“From a clinical perspective our results show that individuals seeking help with psychotic symptoms or diagnosed psychosis should be encouraged to stop using cannabis as recommended in various national and international schizophrenia guidelines [55–58].”
Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis
Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw003 · Cited by 899 · cited 2×
“The largest meta-analyses included 66,816 participants [34], and the largest systematic review 113,802 participants [41].”
InfluentialGalletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Research works printed but not linked: 3
- Hoch E, Friemel C, Schneider M (2018) Cannabis: Potenzial und Risiko. In: Hoch E, Friemel C, Schneider M (eds) Eine wissenschaftliche Bestandsaufnahme. Springer, Berlin
- Ocebm (2011) Levels of evidence working group. In: Oxford Centre for Evidence-Based Medicine O (ed), 2nd edn
- Sign (2015) Scottisch intercollegiate guidelines network 50 methodology checklist. Edinburgh, UK
Cited by
Fischer, B., Robinson, T., Bullen, C., Curran, V., Jutras-Aswad, D., Medina-Mora, M. E., Pacula, R. L., Rehm, J., Room, R., Brink, W. V. D., et al. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103381 · Cited by 236
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gaebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 179
Self-Isolation: A Significant Contributor to Cannabis use during the COVID-19 Pandemic
Bartel, S. J., Sherry, S. B., & Stewart, S. H. (2020) · Substance Abuse · doi:10.1080/08897077.2020.1823550 · Cited by 155
“This is a concerning finding given that increasing cannabis use levels in emerging adults are linked with poorer cognitive functioning,(17) greater risk of cannabis-related problems,(18) and increased risk of psychosis.(19) Moreover, cannabis smoking, the most commonly reported method of using cannabis during the pand…”
BackgroundCannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
“Meta-analyses of case–control and cohort studies report a robust association between cannabis use and the risk of a psychotic disorder, and a dose–response relationship between this risk and the frequency of cannabis use [16].”
Self-citationClinical management of cannabis withdrawal
Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 135
“Heavy cannabis use increases psychosis risk, and cannabis use worsens symptoms of schizophrenia [32].”
BackgroundSelf-citation
Metadata
- Authors
- Hasan, A., von Keller, R., Friemel, C. M., Hall, W., Schneider, M., Koethe, D., Leweke, F. M., Strube, W., & Hoch, E.
- Affiliations
- Klinik und Poliklinik für Psychiatrie und Psychotherapie (DE)
- Ludwig-Maximilians-Universität München (DE)
- The University of Queensland (AU)
- The University of Sydney (AU)
- Corresponding author
- Hasan, Alkomiet
- ORCID
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2019-09-28
- Volume
- 270
- Issue
- 4
- Pages
- 403-412
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2976454237
- Cited by
- 257
- References
- 60
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 55 · 2023: 45 · 2022: 38 · 2021: 32 · 2020: 20 · 2019: 1
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- OPUS (Augsburg University) (submittedVersion)
- Funders
- Bundesgesundheitsministerium
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- cannabis use, psychosis, transition to psychosis, relapse, hospitalization, positive symptoms, dose-dependent risk, cannabis and mental health
- MeSH terms
- Marijuana Use, Humans, Psychotic Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis use and psychosis: a review of reviews. https://app.cochat.ai/papers/10.1007/s00406-019-01068-z
- The paper
- Hasan, A., von Keller, R., Friemel, C. M., Hall, W., Schneider, M., Koethe, D., Leweke, F. M., Strube, W., & Hoch, E. (2020). Cannabis use and psychosis: a review of reviews. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-019-01068-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.